Sandoz stock gains 1.23 percent as Morgan Stanley lifts target

Published on 10/07/2026 at 13:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sandoz stock carries a CHF 60 Morgan Stanley target after the bank raised it from CHF 55 on October 6, 2026. First-half sales reached USD 5.8 billion.

Sandoz, CH1243598427, Illustration mit AI erstellt.

Sandoz stock was trading at CHF 70.62 on the SIX Swiss Exchange on October 7, 2026 at 1:27 p.m. CEST, up 1.23 percent from CHF 69.76. The immediate analyst catalyst was Morgan Stanley, which raised its price target to CHF 60 from CHF 55 on October 6 while keeping an Underweight rating, as Markets Insider reported.

Analyst targets diverge

The Morgan Stanley target remains below the SIX price, but the broader view is more constructive. Markets Insider said Barclays maintained a Buy rating with a CHF 93.00 target on October 6, while its report cited a Moderate Buy consensus and an average target of CHF 80.08.

Against the CHF 70.62 market price, that consensus target stands 13.4 percent higher. The contrast between Morgan Stanley's Underweight view and Barclays' Buy rating makes the target range a central issue for investors tracking Sandoz's valuation.

First-half growth supports the case

Sandoz reported a stronger operating profile for the first half of 2026. Its net sales increased 5 percent at constant currencies to USD 5.8 billion, while biosimilar sales grew 20 percent, according to the company's Q2 earnings call transcript published by Yahoo Finance.

Core EBITDA rose 15 percent and the core EBITDA margin expanded 90 basis points to 20.9 percent in the same period. Management confirmed its 2026 guidance, including mid- to high-single-digit constant-currency sales growth and a core EBITDA margin increase of about 100 basis points.

Stock remains below its yearly high

The intraday range on October 7 extended from CHF 69.22 to CHF 70.96. Sandoz remains below its 52-week high of CHF 75.90 and above its 52-week low of CHF 47.45, leaving the current quotation 6.96 percent below the high.

Market capitalization stood at CHF 30.6 billion on October 7, 2026. The combination of higher biosimilar growth and wider margins supports the bullish analyst case, while the conflicting Morgan Stanley rating shows that execution and pricing remain important valuation tests.